Navigation Links
NIH announces phase III clinical trial of creatine for Parkinson's disease

The NIH National Institute of Neurological Disorders and Stroke (NINDS) today is launching a large-scale clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD). While creatine is not an approved therapy for PD or any other condition, it is widely thought to improve exercise performance. The potential benefit of creatine for PD was identified by Parkinson’s researchers through a new rapid method for screening potential compounds.

The double-blind, placebo-controlled, phase III study is one of the largest PD clinical trials to date. It will enroll 1720 people with early-stage PD at 51 medical centers in the United States and Canada.

"This study is an important step toward developing a therapy that could change the course of this devastating disease," says Elias A. Zerhouni, M.D., director of the NIH. "The goal is to improve the quality of life for people with Parkinson's for a longer period of time than is possible with existing therapies." Currently there is no treatment that has been shown to slow the progression of PD.

The trial is the first large study in a series of NINDS-sponsored clinical trials called NET-PD (NIH Exploratory Trials in Parkinson's Disease). NINDS has organized this large network of sites to allow researchers to work with PD patients over a long period of time, with a goal of finding effective and lasting treatments. NET-PD builds on a developmental research process—from laboratory research to pilot studies in a select group of patients, to the definitive phase III trial of effectiveness in people with Parkinson’s disease.

"This study is an example of the Institute's commitment to Parkinson's research," says NINDS director Story C. Landis, Ph.D. "We are trying to explore every possible option for reducing the burden of this disease."

Participants will be in the phase III study for five to seven years. The effort will be led by Ka rl Kieburtz, M.D., M.P.H., of the University of Rochester in New York, and Barbara C. Tilley, Ph.D., of the Medical University of South Carolina in Charleston, and the patients will be seen by movement disorders specialists at the NET-PD sites across the United States and Canada.

PD is a degenerative disorder of the brain in which patients develop symptoms such as progressive tremor, slowness of movements, and stiffness of muscles. It affects at least one million people in the United States. Although certain drugs, such as levodopa, can reduce the symptoms of PD, there are no proven treatments that can slow the progressive deterioration in function.

Creatine is marketed as a nutritional supplement. Studies have suggested that it can improve the function of mitochondria, which produce energy inside cells. It also may act as an antioxidant that prevents damage from compounds that are harmful to cells in the brain. In a mouse model of PD, creatine is able to prevent loss of the cells that are typically affected.

"Creatine, or any compound that may slow the progression of PD, could have very important long-term benefits for people who are living with this disease," says John R. Marler, M.D., NINDS associate director for clinical trials.

The study will enroll people who have been diagnosed with PD within the past five years and who have been treated for two years or less with levodopa or other drugs that increase the levels of dopamine in the brain. Many of the symptoms of PD result from the loss of dopamine, a neurotransmitter that helps to control movement. Half of the participants will receive creatine and half will receive a placebo. Neither the participants nor their doctors will know which treatment they receive.

"We are studying a stage of the disease that usually hasn't been included in clinical studies," notes Dr. Kieburtz. The study is designed to include a broad range of people, with special efforts to recruit a diverse population that is similar to the makeup of the population with PD in the United States.

The investigators will measure disease progression using standard rating scales that measure quality of life, ability to walk, cognitive function, and the ability to carry out other activities of daily living.


'"/>

Source:NIH/National Institute of Neurological Disorders and Stroke


Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
4. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
5. GlycoFi announces the first production of antibodies with human glycosylation in yeast
6. NHGRI announces new sequencing targets
7. CHAVI announces international search for genes affecting HIV response
8. NHGRI announces latest sequencing targets
9. MUHC announces a transplant first in Quebec
10. St. Jude announces breakthrough in eye cancer treatment
11. Worlds largest rainforest drying experiment completes first phase
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
(Date:1/21/2016)... , January 21, 2016 ... a new market research report "Emotion Detection and Recognition ... Software Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020", published by MarketsandMarkets, the ... to reach USD 22.65 Billion by 2020, at ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... FREDERICK, Md. , Feb. 8, 2016 /PRNewswire/ ... advanced consumer medical devices, announced today that it ... for administrative proceedings from the Securities and Exchange ... Richard Staelin , Chairman of the Board ... Donnell Professor of Business Administration at The Fuqua ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... a wide range of loose, bulk foods at various stages of the production ... also used to inspect large bulk products post packaging such as sacks of ...
(Date:2/8/2016)... Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral ... will present information about the company,s programs at the BIOCEO conference ... York City . --> --> ... EST. Registered attendees can request a one on one meeting through ... --> New York City . ...
(Date:2/8/2016)... Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, Feb. ... Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create a ...
Breaking Biology Technology: